» Articles » PMID: 24423027

Evidence from a Breast Cancer Hypofractionated Schedule: Late Skin Toxicity Assessed by Ultrasound

Overview
Publisher Biomed Central
Specialty Oncology
Date 2014 Jan 16
PMID 24423027
Citations 11
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Feasibility of whole breast hypofractionated radiotherapy schedules in breast conserving therapy is recognized however concerns remain about the role of the boost dose on the overall treatment's potential toxicity. In this study we report on the possibility to quantitatively evaluate radiation induced toxicity in patients treated with an abbreviated course with major concern in the irradiated boost region.

Methods: Eighty-nine patients who underwent conservative surgery for early-stage breast cancer followed by adjuvant accelerated hypofractionated whole breast radiotherapy were included in this study to assess skin and subcutaneous tissue late toxicity by means of ultrasonographic quantitative examination. For each patient the skin thickness was measured at four positions: on the irradiated breast, in the boost region and in the corresponding positions in the contra-lateral not treated breast. All patients were scanned by the same radiologist to reduce potential inter-operator variability, the operator was blind to the scoring of the patient CTCv3 late toxicity as well as patient treatment characteristics. Ultrasound assessment and clinical evaluation were compared.

Results: The median time between the end of adjuvant radiotherapy and ultrasound examination was 20.5 months. The measured mean skin thickness in the irradiated breast was 2.13 ± 0.72 mm while in the mirror region of the contra-lateral healthy breast was 1.61 ± 0.29 mm. The measured mean skin thickness in the irradiated boost region was 2.25 ± 0.79 mm versus 1.63 ± 0.33 mm in the corresponding region of contra-lateral healthy breast. The mean increment in skin thickness respect to the counterpart in the healthy breast was 0.52 ± 0.67 mm and 0.62 ± 0.74 mm for the breast and the boost region respectively. A significant direct correlation was found between the increment in skin thickness in the irradiated breast and in the boost region with fibrosis (G ≥ 1).

Conclusions: In this study results from a breast cancer hypofractionated schedule in terms of late skin toxicity are reported. In particular our study confirms that late cutaneous reactions can be reliably assed by ultrasonographic examination, also discriminating between regions irradiated at different doses, and that this instrumental evaluation is in agreement with clinical stated toxicity.

Citing Articles

Ultrasound Findings After Breast Cancer Radiation Therapy: Cutaneous, Pleural, Pulmonary, and Cardiac Changes.

Catalano O, Fusco R, Carriero S, Tamburrini S, Granata V Korean J Radiol. 2024; 25(11):982-991.

PMID: 39473089 PMC: 11524688. DOI: 10.3348/kjr.2024.0672.


The Assessment of the Long-Term Impact of Radiotherapy on Biophysical Skin Properties in Patients after Head and Neck Cancer.

Pazdrowski J, Polanska A, Kazmierska J, Kowalczyk M, Szewczyk M, Niewinski P Medicina (Kaunas). 2024; 60(5).

PMID: 38792923 PMC: 11122895. DOI: 10.3390/medicina60050739.


Do Barrier Films Impact Long-Term Skin Toxicity following Whole-Breast Irradiation? Objective Follow-Up of Two Randomised Trials.

Dejonckheere C, Lindner K, Bachmann A, Abramian A, Layer K, Anzbock T J Clin Med. 2023; 12(22).

PMID: 38002807 PMC: 10672183. DOI: 10.3390/jcm12227195.


Objective, Clinician- and Patient-Reported Evaluation of Late Toxicity Following Adjuvant Radiation for Early Breast Cancer: Long-Term Follow-Up Results of a Randomised Series.

Dejonckheere C, Abramian A, Lindner K, Bachmann A, Layer K, Anzbock T J Clin Med. 2023; 12(13).

PMID: 37445247 PMC: 10342564. DOI: 10.3390/jcm12134212.


Ultrasonographic Evaluation of Skin Toxicity Following Radiotherapy of Breast Cancer: A Systematic Review.

Hussein F, Manan H, Mustapha A, Sidek K, Yahya N Int J Environ Res Public Health. 2022; 19(20).

PMID: 36294025 PMC: 9603505. DOI: 10.3390/ijerph192013439.


References
1.
Chadha M, Woode R, Sillanpaa J, Lucido D, Boolbol S, Kirstein L . Early-stage breast cancer treated with 3-week accelerated whole-breast radiation therapy and concomitant boost. Int J Radiat Oncol Biol Phys. 2013; 86(1):40-4. DOI: 10.1016/j.ijrobp.2012.11.010. View

2.
Cox J, Stetz J, Pajak T . Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995; 31(5):1341-6. DOI: 10.1016/0360-3016(95)00060-C. View

3.
Bantema-Joppe E, van der Laan H, de Bock G, Wijsman R, Dolsma W, Busz D . Three-dimensional conformal hypofractionated simultaneous integrated boost in breast conserving therapy: results on local control and survival. Radiother Oncol. 2011; 100(2):215-20. DOI: 10.1016/j.radonc.2011.05.027. View

4.
Deantonio L, Gambaro G, Beldi D, Masini L, Tunesi S, Magnani C . Hypofractionated radiotherapy after conservative surgery for breast cancer: analysis of acute and late toxicity. Radiat Oncol. 2010; 5:112. PMC: 3000406. DOI: 10.1186/1748-717X-5-112. View

5.
Chadha M, Vongtama D, Friedmann P, Parris C, Boolbol S, Woode R . Comparative acute toxicity from whole breast irradiation using 3-week accelerated schedule with concomitant boost and the 6.5-week conventional schedule with sequential boost for early-stage breast cancer. Clin Breast Cancer. 2011; 12(1):57-62. DOI: 10.1016/j.clbc.2011.09.002. View